Psychedelics Drug Development: Navigating the Science, Regulatory & Outsourcing Landscape

Over the past decade, there has been a surge of interest in psychedelics as a novel treatment choice for mental health conditions including depression and post-traumatic stress disorder (PTSD) as well as for CNS conditions. Psychedelics are a class of psychoactive substances that produce changes in perception, mood, and cognitive processes. Growing evidence from scientific studies suggests that treatments that include a psychedelic such as psilocybin, N,N-dimethyltryptamine (DMT), lysergic acid diethylamide (LSD), ketamine derivatives and 3,4-methylenedioxymethamphetamine (MDMA) could provide new choices for doctors and their patients to treat these conditions due to targeting different areas of the brain that current methods do not access.

Navigating the development of these new classes of therapies can be complex. Learn more about these considerations from the perspective of a drug development accelerator (CRO/CDMO) and factors to keep in mind when selecting a partner for the development of your next psychedelics therapeutic in our next webinar.

Join our speakers Richard Castledine, Head of Drug Substance and Translational Pharmaceutics Operations, Alan McNeill, Head of Isotope Labelling, and Mark Anstiss, Head of Drug Substance Production, as they delve into the many challenges faced in the development of psychedelic APIs, derivatives, and analogues. Dr. Castledine, Dr. McNeill, and Dr. Anstiss will explain how Quotient Sciences and our team of experts can support the development of your API and help you reach your development milestones in this exciting and fast-moving area.

Key takeaways:

• How the development landscape has evolved with a recent resurgent interest in psychedelic compounds
• How to address challenges around scale up and 14C synthesis of psychedelic compounds
• How to operate compliantly with these compounds, and the related EH&S, legal, and regulatory considerations that must be considered 
• How Quotient Sciences has applied its experience with compounds derived from and related to cannabinoids, psilocybin, and ketamine to the development of new therapies

Who should attend:

• Professionals responsible for the development of small molecule psychedelic APIs at biotechnology start-ups and small/midsize pharmaceutical companies
• Outsourcing managers
• Drug development consultants

Register now